Genomic Health Ties Up With Biocartis, Boosts Oncotype DX
Zacks Investment Research | Sep 13, 2017 10:31PM ET
Genomic Health, Inc. (NASDAQ:GHDX) and Biocartis Group NV (BCART) signed an agreement to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Scoretest on Biocartis' proprietary Idylla platform. This can be performed locally by laboratory partners as well as hospitals globally. Biocartis is an innovative molecular diagnostics company providing next generation diagnostic solutions.
According to Genomic Health, the Oncotype DX Breast Recurrence Score test evaluates the activity of 21 genes in a patient's breast tumor tissue. This provides customized treatment options based on the biology of the patients’ individual disease. The company claims this to be the only proven test to predict chemotherapy benefit. Consequently, this is included in all major cancer guidelines worldwide. Further, the test is considered standard of care for early-stage breast cancer.
Biocartis' Idylla platform provides a unique solution that is unparalleled in the localization of complex molecular diagnostics. Based on the advanced features of the Idylla platform, Genomic Health expects local pathology labs to generate Oncotype DX Breast Recurrence Score results with minimal labor and efficient turnaround time. The company also looks forward to maintaining the high quality and clinical utility that physicians and patients expect from Oncotype DX.
This agreement will provide Genomic Health rights to develop and commercialize Oncotype DX Breast Recurrence Score test on the Idylla platform. The development of the Oncotype DX IVD test is expected to initiate in late 2017. Genomic Health is anticipated to pay around $3.3 million to Biocartis in the third quarter of 2017. Rest of the payments will be made to Biocartis after achieving few commercial milestones.
Excluding the transaction cost of the partnership, Genomic Health continues to anticipate earning profits in full year 2017. Per the agreement, the company will make royalty payments based on net sales of the IVD tests developed on the Biocartis Idylla platform, post commercialization.
In September, Genomic Health announced that new data shows additional evidence of the unmatched value of the Oncotype DX Breast Recurrence Scoretest in predicting outcomes in early-stage breast cancer patients accurately.
In July, majority of panelists from the St. Gallen International Breast Cancer Conference Expert Panel supported that Oncotype DX was the only test providing information that aided physicians in taking the decision to omit chemotherapy in patients with up to three positive nodes. The panel also published updated guidelines endorsing Oncotype DX for guiding chemotherapy treatment decisions in both node-negative and node-positive breast cancer patients.
In June, five studies in breast cancer were presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, including new analyses from the tie ups with the Surveillance, Epidemiology, and End Results or SEER Registry program. The study focused on outcomes of more than 49,000 women who have received an Oncotype DX Breast Recurrence Score test. One of these analyses examines the risk of breast cancer-specific mortality across the full range of Recurrence Score results and is consistent with previous validation studies.
According to a report by GBI Research, the global breast cancer therapeutics market is estimated to reach $17.2 billion by 2021, at a CAGR of 7.3%. Considering the huge potential of the market, we believe the latest agreement is a strategical fit.
In the past year, Genomic Health has been trading above the broader Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.